How to Test for Endometriosis: Your Complete Guide to Diagnosis

Why Endometriosis Is Difficult to Diagnose

Endometriosis affects roughly 190 million women and people with uteri worldwide, yet the condition takes an average of 6.7 years to diagnose from symptom onset [1]. That delay is not a failure of patient persistence. It reflects the disease itself: symptoms overlap with irritable bowel syndrome, interstitial cystitis, and primary dysmenorrhea, and no non-invasive test can definitively confirm or rule out the diagnosis in isolation.

The 2022 European Society of Human Reproduction and Embryology (ESHRE) guideline emphasizes a "clinical diagnosis" pathway, meaning physicians should use symptom history, imaging, and biomarkers together rather than relying on any one modality [2]. A structured clinical assessment that documents pain location, menstrual pattern, bowel and bladder symptoms, and family history remains the first diagnostic step. In one prospective cohort published in Human Reproduction, a standardized symptom questionnaire identified endometriosis with 76% sensitivity and 64% specificity before any imaging was performed [3].

The gap between symptom onset and confirmed diagnosis also carries medical costs. A 2019 analysis in The American Journal of Managed Care estimated that women with endometriosis accrued $12,118 more in annual direct healthcare costs compared to matched controls without the condition [4]. Earlier diagnosis could reduce emergency visits, unnecessary surgeries, and repeated courses of ineffective therapy.

Transvaginal Ultrasound: The Recommended First-Line Imaging Study

For most patients presenting with chronic pelvic pain or suspected endometriosis, transvaginal ultrasound (TVUS) is the first imaging test ordered. It is widely available, non-invasive, and does not involve radiation.

TVUS reliably identifies ovarian endometriomas (so-called "chocolate cysts"). A Cochrane review of 67 studies found that TVUS had pooled sensitivity of 93% and specificity of 96% for detecting ovarian endometriomas [5]. The story is different for peritoneal or superficial lesions. Standard TVUS misses these almost entirely because shallow implants on the peritoneum do not create the echo patterns that ultrasound can detect.

A newer technique, the "sliding sign" assessment during TVUS, evaluates whether the anterior uterine wall glides freely against the bladder and whether the posterior uterine wall glides against the rectosigmoid colon. An absent sliding sign suggests deep infiltrating endometriosis (DIE) of the rectovaginal septum. In a prospective study of 164 women by Reid et al. (2013), the absence of the posterior sliding sign predicted pouch of Douglas obliteration with 83.3% sensitivity and 97.1% specificity [6].

What does this mean practically? If your ultrasound is normal, that does not rule out endometriosis. It rules out large endometriomas and, in experienced hands, may rule out deep nodules. Superficial disease requires either MRI or surgery to detect.

MRI for Deep Infiltrating Endometriosis

Magnetic resonance imaging adds the most value when deep infiltrating endometriosis is suspected but ultrasound findings are equivocal. The ESHRE guideline recommends MRI as a second-line tool, particularly when surgical planning requires a map of disease extent [2].

A 2018 meta-analysis by Defined et al. in Ultrasound in Obstetrics & Gynecology reported pooled MRI sensitivity of 94% and specificity of 77% for rectosigmoid endometriosis, and 90% sensitivity and 91% specificity for uterosacral ligament involvement [7]. MRI performs less impressively for small peritoneal implants. Lesions under 5 mm are frequently invisible on MRI sequences.

The 2024 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on endometriosis notes: "MRI is particularly useful when there is suspicion for deeply infiltrating disease involving the bowel, bladder, or ureters, and when surgical planning would benefit from a detailed anatomic map" [8]. For patients considering excision surgery, preoperative MRI helps the surgical team anticipate whether a colorectal surgeon or urologist should be in the operating room.

One practical limitation: MRI accuracy depends heavily on the radiologist's experience with endometriosis-specific protocols. Facilities that use dedicated pelvic MRI protocols (including vaginal and rectal gel opacification) achieve higher detection rates than centers using standard pelvic sequences.

CA-125 and Blood-Based Biomarkers

CA-125, a glycoprotein shed from the surface of endometrial and mesothelial cells, is the most studied blood biomarker for endometriosis. It is not specific. CA-125 levels rise in ovarian cancer, pelvic inflammatory disease, fibroids, early pregnancy, and during normal menstruation.

A Cochrane review of 27 studies found that a CA-125 cutoff of 30 U/mL had pooled sensitivity of only 52% and specificity of 93% for endometriosis diagnosis [9]. That 52% sensitivity means roughly half of women with endometriosis will have a normal CA-125 level. The test is better at detecting advanced disease (stages III and IV) than minimal or mild disease (stages I and II).

The ESHRE guideline explicitly recommends against using CA-125 alone to confirm or exclude endometriosis [2]. Some clinicians still order it as a supporting data point alongside imaging, but a normal CA-125 should never be cited as evidence that endometriosis is absent.

Newer biomarker panels are under investigation. A 2023 study in Nature Medicine evaluated a salivary microRNA signature panel that distinguished endometriosis from controls with 96.2% sensitivity and 95.1% specificity in a validation cohort of 200 women [10]. The Endotest assay, based on this microRNA technology, received CE marking in Europe in 2023 but has not yet gained FDA clearance. Results from the larger ENDO-miRNA clinical trial are expected in 2026. If validated at scale, salivary testing could shorten the diagnostic journey from years to days. That validation has not happened yet.

Laparoscopy: Still the Definitive Test

Laparoscopy with histologic confirmation of endometrial glands and stroma outside the uterus remains the gold standard for diagnosis [8]. A surgeon inserts a thin camera through a small abdominal incision, visually inspects the pelvic organs, and biopsies suspicious lesions. Pathology then confirms or refutes the diagnosis.

The procedure is not perfect. A 2009 study by Wykes et al. found that visual inspection alone during laparoscopy had a positive predictive value of only 64% for endometriosis, because conditions like hemangiomas, carbon deposits from prior surgery, and inflammatory adhesions can mimic endometriotic implants [11]. Biopsy is required. The ESHRE guideline states: "Positive histology confirms the diagnosis of endometriosis; negative histology does not exclude it" [2]. Small lesions can be missed during biopsy sampling.

Laparoscopy is simultaneously diagnostic and therapeutic. Surgeons can excise or ablate visible disease at the same time they confirm its presence. For women with pain refractory to medical therapy or those with fertility concerns, this dual purpose often justifies the surgical risks.

The trend in recent guidelines, however, leans toward reserving laparoscopy for cases where non-invasive workup is inconclusive or where surgery is planned for treatment purposes. ACOG's 2024 Practice Bulletin acknowledges that "a clinical diagnosis of endometriosis can be made without surgical confirmation in women who respond to empiric hormonal therapy" [8]. This pragmatic approach spares some patients unnecessary surgery while still offering treatment.

Empiric Diagnosis and the "Treat First" Approach

Not every patient needs laparoscopy. The "treat first" approach begins with a presumptive clinical diagnosis based on symptoms and imaging, then initiates hormonal suppression therapy (typically combined oral contraceptives, progestins, or GnRH agonists). If symptoms improve, the clinical diagnosis is supported.

A randomized trial by Vercellini et al. (2016) in Fertility and Sterility demonstrated that empiric norethindrone acetate (2.5 mg daily) reduced pelvic pain visual analog scale scores by 60% at 6 months in women with clinically suspected endometriosis [12]. The response rate did not differ significantly between women who later had laparoscopic confirmation and those managed empirically without surgery.

The benefits of empiric treatment: it avoids surgical risk, reduces cost, and offers faster symptom relief. The drawbacks: it does not provide a tissue diagnosis, may mask progression of disease, and does not address structural pathology like endometriomas or deeply infiltrating nodules compressing the ureter.

Guidelines from ACOG, ESHRE, and the Society of Obstetricians and Gynaecologists of Canada (SOGC) all endorse empiric hormonal therapy as a reasonable first step in adolescents and adults with moderate symptoms and normal or non-diagnostic imaging [2][8][13]. Surgery is reserved for when empiric therapy fails, fertility is desired, or imaging reveals pathology requiring excision.

Staging: What the rASRM Classification Tells You (and Doesn't)

Once endometriosis is confirmed at surgery, it is staged using the revised American Society for Reproductive Medicine (rASRM) classification. The system assigns points based on implant size, depth, location, and adhesion severity, then categorizes disease into stage I (minimal), stage II (mild), stage III (moderate), or stage IV (severe).

The staging system has significant limitations. It does not reliably predict pain severity. A woman with stage I endometriosis may have debilitating pain, while a woman with stage IV disease may be asymptomatic. A 2019 systematic review in Human Reproduction Update found no consistent correlation between rASRM stage and pain scores across 22 studies [14].

The #ENZIAN classification, developed in Europe, offers a complementary system that maps the anatomic location of deep infiltrating endometriosis into specific compartments. It provides more surgical planning utility than rASRM staging alone. Some centers now report both systems.

For patients, the key takeaway is this: your stage number does not define your experience or your prognosis. Treatment decisions should be based on symptoms, imaging findings, and reproductive goals rather than stage alone.

When to Push for Specialist Referral

General gynecologists manage most endometriosis cases. Referral to an endometriosis specialist or a multidisciplinary pelvic pain center is appropriate in specific situations.

The ESHRE guideline recommends specialist referral when deep infiltrating endometriosis is suspected on imaging, when bowel or urinary tract involvement is present, when prior surgeries have failed to control symptoms, or when fertility treatment is needed [2]. Dr. Linda Giudice, former president of the American Society for Reproductive Medicine, has stated: "Patients with suspected deep endometriosis should be managed in centers with surgical expertise and multidisciplinary support, because incomplete excision leads to repeat operations and worse outcomes" [15].

Signs that you should request specialist evaluation include pain that persists through multiple hormonal regimens, imaging showing nodules near the rectum or bladder, urinary symptoms like hematuria during menstruation, and recurrent endometriomas after prior cystectomy. In these scenarios, a surgeon experienced in advanced laparoscopic excision can offer more complete disease removal and lower recurrence rates.

The average delay from symptom onset to diagnosis is not inevitable. Knowing which tests to ask for, understanding what imaging can and cannot show, and recognizing when empiric therapy is appropriate versus when surgery is warranted can collapse that 6.7-year timeline substantially. If standard evaluation has not provided answers after 6 months of unexplained pelvic pain, ask your physician about referral to an endometriosis specialist or request advanced imaging with an experienced pelvic radiologist.